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Three easily-implementable changes
reduce median door-to-needle time for
intravenous thrombolysis by 23minutes
Demi Tran1†, Zhu Zhu1,2†, Mohammad Shafie1, Hermelinda Abcede1, Dana Stradling1 and Wengui Yu1,3*
Abstract
Background: The benefit of intravenous thrombolysis (IVT) for acute ischemic stroke is time dependent. Despite
great effort, the median door-to-needle time (DNT) was 60 min at the United States stroke centers. We investigated
the effect of a simple quality improvement initiative on DNT for IVT.
Methods: This is a single-center study of patients treated with IVT between 2013 and 2017. A simple quality
improvement initiative was implemented in January 2015 to allow the Stroke team to manage hypertension in the
emergency room, to make decision for IVT before getting blood test results unless patients were taking oral
anticoagulants, and to give IVT in the CT suite. Baseline characteristics, DNT and outcomes at hospital discharge
were compared between pre- and post-intervention groups.
Results: Ninety and 136 patients were treated with IVT in pre- and post-intervention groups, respectively. The rate
of IVT was significantly higher in the post-intervention group (20% vs. 14.4%, p = 0.007). The median DNT with
interquartile range (IQR) was reduced significantly by 23 min (63[53–81] vs. 40[29–53], p < 0.001) with more patients
in the post-intervention group receiving IVT within 60 min (81.6% vs. 46.7%) and 45 min (64.0% vs.17.8%). There was
no significant difference in symptomatic intracerebral hemorrhage rate (1.5% vs. 1.1%), modified Rankin Scale 0–1
(29.4% vs. 23.3%), and hospital mortality (7.4% vs. 6.7%) between the 2 groups.
Conclusions: Three easily-implementable quality improvement initiative increases IVT rate and reduces DNT
significantly without increasing the rate of IVT-related complications in our comprehensive stroke center.
Keywords: Acute ischemic stroke, Intravenous thrombolysis, Door-to-needle time, Quality improvement
Introduction
Intravenous thrombolysis (IVT) with tissue-type plas-
minogen activator (tPA) is the proven medical therapy
for acute ischemic stroke (AIS), with faster administra-
tion resulting in better outcomes [1, 2]. However, the
diagnosis and treatment of AIS are often delayed for
various reasons, including lack of pre-notification, un-
clear last-known-well (LKW) time, waiting for blood test
results, lag in getting CT scan and reports of imaging
findings, holdup in mixing tPA or transportation be-
tween emergency room (ER) and CT scan suite, manage-
ment of uncontrolled hypertension, performing CT
angiography and CT perfusion, and determination of eli-
gibility [3–10].
Researchers at Helsinki University Central Hospital in
Finland were able to implement measures to reduce
delays and cut the median door-to-needle time (DNT)
to 20 min with interquartile range (IQR) 14–32min [4].
The Helsinki protocol was successfully replicated at the
Royal Melbourne Hospital to reduce DNT to 25 (IQR,
19–48) minutes during business hours (8 AM to 5 PM
Monday-Friday) in 2012 [5]. A few hospitals in Canada
and Netherlands were also able to reduce median DNT
to 25–37min [6–9].
In contrast, the quality improvement endeavors have not
worked out very well in the United States (U.S.). Despite the
launch of American Heart Association (AHA)/American
Stroke Association (ASA) Target: Stroke initiatives in 2010
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and comprehensive stroke center (CSC) certification by the
Joint Commission in 2012 [10, 11], the IVT rate and median
DNT at the U.S. stroke centers remains suboptimal. A study
of AIS patients registered in Get With The Guidelines-
Stroke from October 2012 to April 2015 showed that the
median DNT was 60min with only 50% patients treated
within 60min [12]. The Target: Stroke phase II was
launched in April 2014. The median DNT from 888 sur-
veyed hospitals between June 2014 and April 2015 was still
56 (IQR, 42–75) minutes [13]. In a recent study comparing
stroke care and outcomes between CSCs and primary stroke
centers (PSCs) in the U.S. from 2013 to 2015, the median
DNT was 52 (IQR, 39–70) minutes at CSCs and 60 (IQR,
47–83) minutes at PSCs [14]. The IVT rates were only 14.3
and 10.3%, respectively.
It appears that centralized hospital system in devel-
oped countries were able to implement quality improve-
ment initiatives efficiently [4–9]. The healthcare system
in the U.S. is decentralized with higher average annual
IVT volume in CSCs than in PSCs (40 vs. 22) [14]. Due
to overall low annual volumes and labor-intensive code
stroke protocols, the stroke centers in the U.S., including
CSCs and PSCs, appear to have significant logistic re-
straints in implementing comprehensive quality improve-
ment initiatives 24/7 [11–13].
Due to limited numbers of vascular neurologists and
insufficient staff support, our stroke center was unable
to implement some of the Stroke: Target phase 1 strat-
egies during 2010 and 2014. We started to focus on the
3 easily-implementable changes in January 2015 to im-
prove stroke care at our CSC. This study aimed to ex-
plore the effect and safety of this simple initiative.
Methods
Patients and design
This is a single-center study approved by the University of
California Irvine Institutional Review Board. Acute Ische-
mic stroke is characterized by the sudden loss of blood
circulation to an area of the brain, resulting in a corre-
sponding loss of neurologic function. Consecutive patients
with LKW within 4.5 h were evaluated for thrombolysis.
Patients receiving IVT at the University of California Irvine
CSC between January 2013 and December 2017 were in-
cluded. A simple quality improvement protocol was devel-
oped in January 2015: 1) To allow the stroke team to
manage hypertension in the ER promptly to keep BP goal
< 185/110mmHg. Patient was initially treated with labetalol
or hydralazine 10mg IV pro re nata and then IV nicardi-
pine infusion at 2.5–15mg/hour to keep steady BP control.
Vital signs were measured every 15 min. 2) To make de-
cision for IVT before getting blood test results (complete
blood count, comprehensive metabolic panel, cardiac en-
zymes and coagulation) unless patients were taking anti-
coagulants. All patients were carefully interviewed and
examined to rule out history of coagulopathies,
thrombocytopenia, and severe metabolic abnormalities
before intravenous thrombolysis and t-PA would be im-
mediately stopped when any potential contraindication
for IVT was found during thrombolysis. All patient got
finger stick for glucose measurement in the ambulance
or Emergency Department (ED). Severe hypoglycemia
was excluded before thrombolysis through finger stick
glucose measurement. The benefit and risk of IVT were
discussed with patients and/or their relatives, and writ-
ten informed consent was not required American Heart
Association guidelines [1]. 3) To give IVT in the CT
suite.
The patients were divided into pre-intervention (January
2013 to December 2014) and post-intervention (January
2016 to December 2017) groups, with one-year washout
period (January 2015 to December 2015) allowing for the
full implementation of the initiative.
The following information was collected and com-
pared between the pre- and post- intervention groups:
age, gender, past medical history (hypertension, diabetes,
hyperlipidemia), National Institutes of Health Stroke
Scale (NIHSS) score at admission, DNT, symptomatic
intracranial hemorrhage (sICH), in-hospital mortality,
and modified Rankin Scale (mRS) at hospital discharge.
sICH was defined as parenchymal hemorrhage type 2
(dense blood clot exceeding 30% of the infarct volume
with substantial space-occupying effect) on CT within
36 h [2].
Statistical analysis
Continuous variables were described by mean ± standard
deviation or median with interquartile range (IQR) based
on the results of normality testing. Categorical variables
were expressed by counts with percentages. Baseline
characteristics and outcomes at discharge were com-
pared between pre- and post- intervention groups by t
test or Wilcoxon rank-sum test for continuous variables
and χ2 test for categorical variables. The proportions of
sICH, functional independence (mRS 0–1), poor out-
come (mRS 5–6), and in-hospital mortality were further
compared between the 2 groups using multivariate logis-
tic regression analysis after adjusting for age, hyperten-
sion, diabetes, hyperlipidemia and baseline NIHSS score.
Analyses were performed using SPSS software (IBM,
Version 23). A 2-tailed value of P < 0.05 was considered
statistically significant.
Results
A total of 1305 patients with AIS were admitted to our
medical center during the study period and 294 of them
received and completed IVT. After excluding 68 patients
treated during the transitional year of the quality improve-
ment initiative, there were 90 patients in pre-intervention
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group (from January 2013 to December 2014) and 136 in
post-intervention group (from January 2016 to December
2017). The demographics and treatment benchmarks of
the 2 groups are shown in Table 1. Compared with pre-
intervention group, significantly more patients were
treated with IVT in the post-intervention group (20.0% vs.
14.4%; OR = 1.39; p = 0.007). There was no difference in
patient age, gender, history of hypertension or diabetes be-
tween the 2 groups. The post-interventional group had
significantly higher rate of hyperlipidemia and lower
NIHSS scores at admission than pre-intervention group.
The patients with minor stroke (NIHSS ≤4) appeared to
be more likely to receive IVT in the post-intervention
group (27.2% vs. 10.0%, p < 0.001).
The median DNT was reduced by 23min from 63 (IQR,
53–81) minutes in the pre-intervention group to 40 (IQR,
29–53) minutes in the post-intervention group (p < 0.001),
with a trend of continuous improvement from 2013 to
2017 (Fig. 1). In addition, significantly more patients in
the post-intervention group received IVT within 60min
(81.6% vs. 46.7%, p < 0.001) and 45min (64.0% vs. 17.8%,
p < 0.001) than in the pre-intervention group. Of note,
there was no significant difference in DNT between pa-
tients with minor (NIHSS ≤4) and major (NIHSS > 4)
stroke (median 50min, IQR 25–75min vs. median 50
min, IQR 36–71min; p = 0.317).
The rates of sICH and functional outcomes at hospital
discharge are summarized in Table 2. There was no sig-
nificant difference in the rates of sICH (1.5% vs. 1.1%),
functional independence (mRS 0–1, 29.4% vs. 23.3%),
and hospital mortality (7.4% vs. 6.7%) between the 2
groups. There was a trend of better functional outcome
(more patients with mRS 0–1 and significantly less pa-
tients with mRS 5–6) in the post-intervention group
(Table 2 and Fig. 2). However, in the multi-variate regres-
sion models, there was insignificant difference between
the 2 groups after adjusting for age, hypertension, hyper-
lipidemia, diabetes and NIHSS score at admission.
Discussion
With a simple and easily-implementable quality im-
provement initiative, we have increase IVT rate from
14.4 to 20.0% and reduced median DNT by 23 min to
40min. Our results are better than recently reported
benchmarks of 14.3% IVT rate and 52min DNT at the
134 CSCs in the U.S. [14].
Despite significant improvement, our results are still
suboptimal compared with the benchmarks from central-
ized Hospital Systems in other developed countries [4–9].
For example, the hospital district of Helsinki and Uusimaa
has a population of 1.6 million and a centralized regional
emergency medical service (EMS) [4, 15]. All patients
deemed as candidates for stroke therapies are transported
with high priority and pre-notification to the Helsinki
University Hospital, which is the only 24/7 neurology
service to provide care for AIS. As a high volume and cen-
tralized Stroke center, the Helsinki University Hospital
was very efficient due to thorough training for all EMS
and ED staff, and long-standing experience [4, 15].
In contrast, our CSC, the only academic medical cen-
ter in Orange County, California, is one of the 9 stroke
receiving centers serving a population of 3.19 million
[16]. In such decentralized healthcare system, it is very
challenging for all of the 9 stroke receiving centers to
implement comprehensive protocols to achieve the fast-
est DNT for IVT [4–11, 14].
Our quality improvement initiative is easily-
implementable, effective and safe. Uncontrolled hyper-
tension is one of the most frequently reported factors
causing delayed DNT [5, 8, 17]. In a single center study,
uncontrolled hypertension was associated with more
than 30 min delay in DNT [16]. Per AHA/ASA
Table 1 Demographics and clinical features of patients in the pre-intervention and post-intervention groups
Variables Pre-intervention Post-intervention OR (95% CI) p value
Age 70 + 16 71 + 17 – 0.745
Male 44 (48.9) 68 (50.0) 1.04 (0.61–1.78) 0.870
Hypertension 62 (68.9) 107 (78.7) 1.67 (0.91–3.06) 0.097
Diabetes 22 (24.4) 46 (33.8) 1.58 (0.87–2.87) 0.132
Hyperlipidemia 29 (32.2) 62 (45.6) 1.76 (1.01–3.07) 0.045
SBP≥ 185/110mmHg 21(23.3) 41 (30.1) 1.44 (0.81–2.54) 0.215
NIHSS 14 (8–21) 7 (4–16) – < 0.001
NIHSS ≤4 9 (10.0) 37 (27.2) 3.36 (1.53–7.38) 0.002
DNT 63 (53–81) 40 (29–53) – < 0.001
DNT < 60 min 42 (46.7%) 111 (81.6%) 5.08 (2.79–9.26) < 0.001
DNT < 45 min 16 (17.8%) 87 (64.0%) 8.20 (4.31–15.3) < 0.001
Data are n (%), mean ± standard deviation, or median (interquartile range)
OR Odds ratio, CI Confidence interval, SBP Systolic blood pressure, NIHSS National Institues of Health Stroke Scale, DNT Door-to-needle time
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guidelines, IVT should be held until BP is less than 185/
110 mmHg [1]. In the pre-intervention group, severe
hypertension was managed by the ER physicians. During
post-intervention period, stroke team was managing
hypertension in the CT suite and ED without any delay
as soon as patient was deemed to be eligible for IVT.
This simple change effectively minimized hypertension-
related delay for IVT.
Waiting for blood testing results is another common
reason for delay up to 60 min in some eligible patients
[5, 18]. Previous studies reported extremely low rates of
unidentified coagulopathies and thrombocytopenia that
would have been a contraindication for IVT [18–20].
Therefore, we implemented the initiative for IVT admin-
istration without waiting for blood test results unless
patients were taking anticoagulants or had history of se-
vere thrombocytopenia. There was no significant differ-
ence in the rate of sICH between pre-intervention and
post-intervention groups. No patient suffered sICH from
IVT due to undiagnosed coagulopathy. In addition, the
rates of sICH in our cohort were much lower than re-
ported in clinical trials [2], confirming the safety of our
simple initiative.
Another change we made in practice in January 2015 was
to give IVT in the CT suite. As CT imaging is an indispens-
able diagnostic tool for decision-making for IVT, shorten-
ing the CT imaging-to-needle time may significantly
improve DNT [4, 5, 21, 22]. Our data confirmed that giving
IVT in the CT suite minimizes the delay from CT to needle
time without significant risk of complications.
Of note, the initial NIHSS scores in the post-
intervention group was significantly lower than that in the
pre-intervention group. There were numerous possibilities
to explain why more patients with non-disabling stroke
(NIHSS ≤4) during the post-intervention group. Previous
studies showed longer DNT in patients with minor stroke,
possibly due to higher chance of atypical symptoms, de-
layed neurology notification and diagnosis [23, 24]. The
Fig. 1 Median door-to-needle time from 2013 to 2017
Table 2 Outcomes in the pre- and post-intervention groups at discharge
Outcomes Patients receiving IVT OR
(95% CI)
p value Adjusted
OR
(95% CI)a
p valuea
Pre-intervention
(n = 90)
Post-intervention
(n = 136)
sICH 1 (1.1) 2 (1.5) 1.33
(0.12–14.87)
0.817 1.15
(0.11–12.39)
0.911
mRS 0–1 21 (23.3) 40 (29.4) 1.37
(0.74–2.53)
0.314 1.01
(0.50–2.04)
0.983
mRS 5–6 39 (43.3) 34 (25.0) 0.44
(0.25–0.77)
0.004 0.53
(0.27–1.05)
0.068
mortality 6 (6.7) 10 (7.4) 1.11
(0.39–3.17)
0.844 1.33
(0.44–4.03)
0.619
Data are n (%)
sICH Symptomatic intracranial hemorrhage, OR Odds ratio, CI Confidence interval, IVT Intravenous thrombolysis, mRS Modified Rankin Scale
aAdjusted for age, hypertension, diabetes, hyperlipidemia and baseline NIHSS
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early diagnosis and decision making from better imple-
mentation of the Stroke: Target strategies in the post-
intervention group would naturally increase IVT for
patients with minor strokes. In addition, better stroke
aware, risk management and stroke prevention in recent
years may have also decreased the ratio of patients with
more severe stroke.
The strength of our study is the use of 3 easily-
implementable changes to reduce DNT without add-
itional infrastructure cost or undue burden on the stroke
team and ED staff. This simple initiative is effective, safe
and easily replicable at other CSCs and PSCs in the U.S.
and other countries.
This study has some limitations. First, it is a single
center study. We used pre-intervention period as his-
toric control. Our post-intervention data could be af-
fected by unmeasurable confounding factors and gradual
improvement in stroke care due to better training and
experience. Second, although we had a one-year transi-
tion period for full implementation of the 3 changes,
there might be incomplete adherence during the post-
intervention period. Since incomplete adherence to the
changes would likely lead to prolonged DNT, it is pos-
sible that the simple changes could work better if the
initiative was applied all the time effectively. Third, as
the aim of this study is to investigate the effect of a sim-
ple quality improvement initiative on DNT for IVT,
some factors associated with outcomes at discharged
were not included (eg, early ischemic changes on im-
aging, large artery occlusions, thrombectomy treatment).
Finally, we have not addressed other hurdles in delaying
DNT, such as point of care coagulation testing for
patients taking anticoagulants, moving directly from the
EMS stretcher to CT scanner [4, 7, 15]. Additional
easily-implementable changes at decentralized healthcare
system may significantly reduce DNT at CSCs and PSCs
in the U.S.
Conclusions
We demonstrated that three easily-implementable changes
increase IVT rate and reduce DNT for IVT significantly
without increasing the rate of IVT-related complications in
our CSC.
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